RHD Advocacy Sudan

  • 03 February 2015

 Right to left: Bongani Mayosi, Sulafa Ali and Satti A Raheem (front row). 

Abdelmoneim Elseed, Sirag M Khair, Abdullah Al Amin and Mohamed Al Amin (back row)

Right to left: Rajaa El Mahdi, Alaa Ghamrawi, Naima Wageea Allah

 

The aim of the meeting was to support primary prevention of ARF/RHD by strong advocacy amongst stakeholders and to come up with joint recommendations regarding strep throat management.

Summary of Presentations:

Prof Bongani presented evidence for cost effectiveness of primary prevention and South Africa’s experience. Sulafa Ali presented methods of diagnosis of sore throat in the world and the criteria used in endemic countries and the WHO. She concluded that Sudan’s program which considers 2 clinical criteria is evidence based and correlates with regional guidelines. This was also assured by Dr. Ghamrawi who stated that in Egypt they use similar criteria. ENT Doctors presented their findings which showed diverse clinical practices however, they are planning to carry out training workshops for their doctors.

All speakers agreed that benzathine penicillin G (BPG) is the drug of choice; however, concerns about availability and quality were real. Dr. Rajaa and Dr. Mohamed Ali explained that there is almost a single brand of BPG from China and that the companies are not interested to import others. The demand for BPG is estimated to rise by 5 fold. Two studies are planned to test bioavailability and bioequivalence of BPG. 

This was a joint PASCAR/WHF program supported by Bupa.

The event was published in Khartoum Media Center 

blog comments powered by Disqus

News & Events